# Colchicine Use for Primary Prevention of Coronary Artery Disease

Study · id `cardio:ct-nct05175274` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05175274](<https://clinicaltrials.gov/study/NCT05175274>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05175274

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 6792 participants.

## Technical summary

Registry record NCT05175274. Randomized; double masking; primary purpose prevention. Start 2022-12-06 (anticipated); primary completion 2027-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 6792 participants (planned count; ClinicalTrials.gov record NCT05175274, source copy `cardio:ctgov-nct05175274-2022-03-21`, retrieved 2026-10-26)
- Planned start: 2022-12-06 (anticipated) (ClinicalTrials.gov record NCT05175274, source copy `cardio:ctgov-nct05175274-2022-03-21`, retrieved 2026-10-26)
- Primary completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT05175274, source copy `cardio:ctgov-nct05175274-2022-03-21`, retrieved 2026-10-26)
- Completion: 2028-07-01 (anticipated) (ClinicalTrials.gov record NCT05175274, source copy `cardio:ctgov-nct05175274-2022-03-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05175274, source copy `cardio:ctgov-nct05175274-2022-03-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05175274-2022-03-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Colchicine Use for Primary Prevention of Coronary Artery Disease
- Condition: Coronary Artery Disease
- Intervention (Drug): Colchicine
- Intervention (Drug): Placebo
- Lead sponsor: Qingdao Central Hospital
- Lead sponsor class: OTHER
- Collaborator: Qingdao Municipal Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Qingdao Central Hospital (`cardio:org-qingdao-central-hospital`)

## Provenance

Content hash: 619cfe0f0a8947d63c715efda2bebf8f14abf33d7f3871b5c63337de923c95d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
